• About
• Links
• Contact
• Sitemap

Sitemap > News > Metabolic & Hormonal Disorders

• Indevus Reports Positive Data From Phase III NEBIDO Trial
• Surface Logix Starts Phase 2A Clinical Trial of SLx-4090 in Dyslipidemia
• Schering-Plough and Bayer Healthcare Announce Availability of ZETIA in Japan, the First Cholesterol-Lowering Agent With a Novel Mechanism of Action Approved in Japan in 18 Years
• Phase III clinical trial with 4-month long-acting formulation of triptorelin: Ipsen decides not to perform further administration
• Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
• DEPOMED INITIATES DOSING OF PATIENTS IN PHASE 2 TRIAL FOR GABAPENTIN GR FOR THE TREATMENT OF MENOPAUSAL HOT FLASHES
• FDA Advisory Committee did not recommend approval of rimonabant (Zimulti®) for use in obese and overweight patients with associated risks factors
• LCT successfully transplants first diabetes patient
• Keryx Biopharmaceuticals Announces Completion of Patient Randomization Into Sulonex Phase III Pivotal Study
• Surface Logix Starts Phase 2A Clinical Trial of SLx-4090 in Dyslipidemia
• Metabasis Therapeutics Announces Initiation of a Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
• Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
• VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
• New data from multiple studies show Galvus® delivers consistent and robust blood sugar control in patients with type 2 diabetes
• Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
• Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
• Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe
• Late Breaking Data Released at ADA Showed that the Investigational Use of JANUVIA™ (sitagliptin) and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
• BYETTA® Study Showed Comparable Blood Glucose Control to Insulin
• BYETTA® Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
• Amlodipine and Olmesartan Study Results Released
• SYMLIN(R) Used in Conjunction with Basal Insulin in Patients with Type 2 Diabetes
• Orexigen™ Therapeutics Reports Contrave™ Has Positive Effect on Visceral Fat and Insulin Resistance, Factors Believed to Contribute to the Risk of Heart Disease and Type II Diabetes
• BENTLEY REPORTS POSITIVE RESULTS WITH NASULIN INTRANASAL INSULIN SPRAY AT THE AMERICAN DIABETES ASSOCIATION MEETING
• Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
• First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
• DiObex Presents Phase 2a Data of DIO-902
• Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
• Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses
• For any given level of HbA1c, Lantus demonstrates less confirmed hypoglycemia over Insulin NPH
• Apidra Improved A1C In People With Type 2 Diabetes When Added to Basal Insulin And Oral Antidiabetic Treatments (BOT)
• Obecure Completes Treatment of Patients in Phase II Obesity Trial
• Generex Biotechnology to Initiate Phase III Clinical Trial of Generex Oral-lyn in 2007 Third Quarter
• CYTOCHROMA REPORTS POSITIVE PHASE I CLINICAL DATA FOR CTA018 INJECTION
• SPEEDEL REPORTS SUCCESSFUL SPP635 PHASE IIA TRIAL IN HYPERTENSION
• Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
• Two Phase III clinical trials on corifollitropin alfa (Org 36286) reach randomization target
• Positive Trial Results - Combination Contraceptive Sprays
• GTx Initiates Phase IIb Ostarine Clinical Trial for Cancer Cachexia
• TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
• CORCEPT THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION FOR CORLUX® TREATMENT OF CUSHING’S SYNDROME
• LifeCycle Pharma to Initiate Phase II Clinical Trial of LCP-AtorFen for the Treatment of High Cholesterol Levels
• Tranzyme Receives FDA Fast Track Designation for TZP-101
• Hollis-Eden Pharmaceuticals Reports Initial Results in Phase I Clinical Trial of HE3286 as New Type II Diabetes Treatment
• Metabasis Therapeutics Announces CS-917 Phase 2b Clinical Trial Results and Reports on Status of Pradefovir
• Metabolex Announces Full Enrollment of Phase 2/3 Study of MBX-102/JNJ 39659100 in Patients with Type 2 Diabetes
• Aclasta recommended for European approval as the first once-yearly treatment for women with postmenopausal osteoporosis
• Tercica Completes Enrollment of Clinical Trial MS301 Evaluating Treatment with Increlex in Children with Primary IGFD
• Wyeth Receives Approvable Letter From FDA for PRISTIQ for the Treatment of Vasomotor Symptoms Associated With Menopause
• Athersys Begins Phase I Trial for ATHX-105 for Treatment of Obesity
• Tranzyme Initiates Dosing of Patients Phase IIb Clinical Trial with TZP-101
• Lybrel, First Low Dose Combination Oral Contraceptive with Unique 365-Day Dosing, Now Available in U.S.
• FDA Advisory Panel votes 22 to 1 for Avandia® to remain available to patients in the US
• First patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307)
• Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus
• Unigene Initiates Oral Calcitonin Clinical Study in Humans
• Positive Phase 1b transdermal insulin clinical trial results
• Tercica Receives Marketing Approval for Increlex in the European Union
• Sirtris Pharmaceuticals, Inc. Announces Initiation of Phase 1b Clinical Trial of SRT501 in MELAS
• DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
• CombinatoRx Announces Initiation of Phase 2a Proof-of-Concept Clinical Study with CRx-401 for Type 2 Diabetes
• Reclast® receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis
• Liraglutide improves glucose control and lowers body weight in two phase 3 studies comprising more than 2,000 patients
• Sirtris Pharmaceuticals Initiates Phase 2a Clinical Trial in Patients with Type 2 Diabetes
• QuatRx Completes Patient Enrollment In Phase 3 Study Of Ophena™ In Women With Postmenopausal Vaginal Syndrome
• AtheroGenics Announces First Patients Enrolled in ANDES Phase III Diabetes Clinical Trial
• Merck Announces FDA Acceptance of NDA for CORDAPTIVE™ (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
• Karo Bio Updates Status of Internal Projects
• Obecure Phase II Trial Shows Positive Results For Histalean(TM) In Obese Women Under 50
• Merck\'s Investigational Lipid-Modifier, CORDAPTIVE™ (ER niacin/laropiprant), Positively Affected Key Lipid Parameters With Less Flushing, In Data from Phase III Study
• Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR® Fixed-Dose Combination
• Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
• Theratechnologies completes patient recruitment for tesamorelin in confirmatory Phase 3 trial
• Advanced Viral Research Corp. to Initiate Phase II Trial in Cancer Patients
• Alba Therapeutics Announces Clearance of IND for Beta Cell Preservation in Type 1 Diabetes using AT-1001
• OSI Pharmaceuticals Announces Positive Results from a Metformin Drug Interaction Study with Its DP-IV Inhibitor, PSN9301
• XTL BIOPHARMACEUTICALS INITIATES PHASE IIB CLINICAL TRIAL OF BICIFADINE FOR THE TREATMENT OF DIABETIC NEUROPATHIC PAIN
• Corcept Therapeutics Receives FDA Notification Opening IND for Corlux® for the Treatment of Cushing\'s Syndrome
• LCT Receives Approval for DiabeCell® Clinical Trial in NZ
• Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
• Phosphagenics to commence a Phase 2 TPM/Insulin clinical trial
• Quigley Corporation Releases Update on Quigley Pharma’s Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
• Phenomix Initiates Phase 2b Clinical Trial Of PHX1149 For Type 2 Diabetes
• XOMA Initiates Phase 1 European Trial in Diabetes for XOMA 052, a Novel Anti-IL-1 Antibody Designed to Target Diabetes, Rheumatoid Arthritis and Other Inflammatory Diseases
• Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
• FDA Approves Lilly\'s Osteoporosis Drug EVISTA® (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
• Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials with HE3286 in Diseases of Inflammation
• Phase 3 study confirms that liraglutide treatment leads to both glucose and weight reduction with a low risk of hypoglycaemic events
• First osteoporosis study in patients with hip fracture finds once-yearly Aclasta®-Reclast® prevents additional fractures and improves survival
• FDA Accepts Samaritan\'s Cushing\'s SP-6300 IND and Clears Phase II Study
• Acceleron Pharma Presents Positive Phase 1 Results on ACE-011 Increasing Markers of Bone Formation
• Depomed Completes Patient Enrollment in Phase 2 Trial for Gabapentin GR for the Treatment of Menopausal Hot Flashes
• One-Year Data Showed Investigational Use of Initial Combination Therapy with JANUVIA™ (sitagliptin) and Metformin Significantly Improved Blood Sugar Control in Patients with Type 2 Diabetes Compared to Metformin Alone
• Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
• Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
• Zelos Therapeutics Presents Positive Data at ASBMR on Subcutaneous and Inhaled Delivery of Cyclic PTH (1-31) (Ostabolin-C™)
• Eucreas®, a single-tablet combination of Galvus® and metformin, recommended for EU approval for type 2 diabetes
• CytRx Provides Arimoclomol and Iroxanadine Clinical Trial Updates
• DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug-Compliant Subjects in Phase Ib Clinical Study
• Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
• DIAMYD® DIABETES VACCINE EFFECTIVE FOR AT LEAST 21 MONTHS
• Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes
• DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
• Celera Announces Clinical Milestone Payment From Merck
• FDA Approves SYMLIN Pen-Injector Devices Offering Convenience and Accuracy for SYMLIN Use
• DiaMedica announces exciting phase II results for DM-71 in type 2 diabetes trial
• Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
• Theratechnologies Reports Positive 52-Week Phase 3 Results For Its Lead Drug Candidate Tesamorelin
• CardioVascular BioTherapeutics Completes Phase I Wound Healing Trial
• MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
• Merck\'s Investigational CETP-Inhibitor, MK-0859 (anacetrapib), Produced Positive Effects on Lipids with No Observed Blood Pressure Changes in Phase IIb Study
• GENFIT launches two Phase II clinical trials for GFT505
• Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
• First Patient Enrolled in Phase II Cancer Trial
• Akesis Pharmaceuticals Files IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes
• New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Diabetic Foot Infections
• Sciele Completes Enrollment of Patients in Pivotal Phase III Clinical Trial for the Combination of Pravastatin and Fenofibrate
• Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
• Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
• Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
• Hollis-Eden Pharmaceuticals Commencing Phase I/II Clinical Trial with TRIOLEX(TM) (HE3286) in Obese, Insulin Resistant Volunteers
• FDA Approves Supplemental New Drug Applications for JANUVIA™ (sitagliptin)
• Isis Adds New Drug to its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes.
• OREXIGEN™ Therapeutics Initiates its Third Phase III Trial for Contrave™ to Treat Obesity
• Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus®
• European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment
• View Summary OREXIGEN™ Therapeutics Reports a Summary of Results from the Phase IIb Trial of Contrave™ to Treat Obesity
• Further positive preliminary data on Diabecell trial
• VIVUS Announces Qnexa Quality of Life Data
• Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436)
• Osiris Therapeutics Initiates Phase II Clinical Trial Evaluating Prochymal(TM) for Type 1 Diabetes
• Takeda Provides Update on Development Status of TAK-475, An Investigational Compound for Treatment of Hypercholesterolemia
• EPIX Pharmaceuticals Reports Preliminary Findings from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
• FDA Accepts New Drug Application for NEBIDO(R) Submitted by Indevus
• Abbott\'s Investigational SIMCOR® Offers Comparable LDL Lowering to Simvastatin and Significantly Raises HDL and Lowers Triglycerides in Phase III Study
• Phase 2 Trial Results for Exelixis\' XL784 Presented at the 2007 American Society of Nephrology Conference
• SPP100 (TEKTURNA/RASILEZ) DECREASES PROTEINURIA IN DIABETIC PATIENTS
• Merck\'s Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE™) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study
• Osteologix Announces Positive Phase II Study of Its Investigational Osteoporosis Drug, NB S101
• VIVUS Completes Special Protocol Assessment Process for Qnexa Phase 3 Studies
• Toshiba Introduces faCTor64 Study to Improve Early Diagnosis and Treatment of Coronary Artery Disease in Asymptomatic Diabetics
• Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events
• Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function
• AtheroGenics Modifies ANDES Clinical Trial Discontinuing Highest Dose of AGI-1067
• Akesis Pharmaceuticals Files IND for Phase IIa Trial of AKP-020 to Treat Type 2 Diabetes
• AKELA PHARMA ANNOUNCES FINAL POSITIVE RESULTS FROM ITS GROWTH HORMONE RELEASING HORMONE (GHRH) PHASE II TRIAL
• Isis Reports New Data for Mipomersen in Routine High Cholesterol Patients and Provides Cumulative Safety Summary
• KARO BIO INITIATES PHASE IIb CLINICAL STUDY WITH KB2115
• FDA Approves MIRCERA®: First Renal Anemia Treatment with Monthly Maintenance Dosing
• FDA Adds Boxed Warning for Heart Attacks to Anti-Diabetes Drug Avandia
• Cardium Initiates Phase 2b Excellarate Clinical Study for Diabetic Ulcers
• Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
• LifeCycle Pharma Completes Patient Enrollment in Phase II Clinical Trial of LCP-AtorFen for the Treatment of Mixed Dyslipidemia, Initiates 52-Week Open Label Extension Study
• New phase 2 study shows that liraglutide leads to significant weight loss in obese people
• GlaxoSmithKline obtains exclusive US OTC marketing rights to MEVACOR® (lovastatin) from Merck & Co., Inc.
• UCB Announces FDA Filing for lacosamide in the Treatment of Diabetic Neuropathic Pain
• Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
• DiaMedica completes data analysis of DM-71 Phase II trial and updates development plan
• Patient Enrollment Completed in Phase IIb Trial of EpiCept NP-1 in Diabetic Peripheral Neuropathy
• Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
• Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
• KARO BIO HAS INITIATED CLINICAL TRIALS WITH KB3305
• Monotherapy BYETTA® Showed Significant Improvement in Glucose Control and Weight Loss in Adults with Type 2 Diabetes
• Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
• Oculus Innovative Sciences Completes Enrollment of Phase II Trial of Microcyn(R) Technology in Treatment of Mildly Infected Diabetic Foot Ulcers
• Dia-B Progresses ISF402 Development to Phase II
• SPEEDEL ANNOUNCES START OF SPP635 PHASE IIA TRIAL IN DIABETIC PATIENTS
• Phase 1 Clinical Trial Starts for RVX-208
• OREXIGEN™ Therapeutics Initiates Fourth Phase III Trial for Contrave to Treat Obesity
• New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
• VIVUS Initiates Third Qnexa Phase 3 Trial in Obese Patients
• Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
• New Phase III Trial Shows Positive Outcome of lacosamide in Patients with Diabetic Neuropathic Pain
• MicroIslet Holds Positive Pre-IND Meeting for US Based Human Clinical Trial With FDA
• Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
• AtheroGenics Completes Enrollment in ANDES Phase III Clinical Trial of AGI-1067
• Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information
• Lipid Sciences, Inc. Concludes Enrollment in HDL Therapy Clinical Trial
• Corcept Therapeutics Announces Commencement of a Phase 3 Trial for Corlux® for the Treatment of Endogenous Cushing\'s Syndrome
• Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
• DIAMYD FILES US IND FOR PHASE III TRIAL WITH DIABETES VACCINE
• AMAG Pharmaceuticals, Inc. Submits New Drug Application to FDA for Ferumoxytol in Chronic Kidney Disease Patients
• Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
• Metabasis Announces Preliminary Safety and Efficacy Results from an Ongoing Phase 1b Clinical Trial for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia
• Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
• Sirtris Announces Positive Results with Proprietary Version of Resveratrol, SRT501, in a Phase 1b Type 2 Diabetes Clinical Study
• Sangamo BioSciences Initiates Phase 2 Clinical Trial of ZFP Therapeutic in Stem Cell Mobilization
• Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
• Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity
• Incyte to Report Positive Clinical Results from JAK Inhibitor and 11beta-HSD1 Inhibitor Programs and Introduce New Metabolic Program at JPMorgan Healthcare Conference,
• VIVUS Initiates Extension Study with Qnexa for Diabetes
• Merck/Schering-Plough Pharmaceuticals Provides Results of the ENHANCE Trial
• Ligand Partner Pfizer Submits NDA for Fablyn(R)
• PreMD Announces FDA Decision on POC Skin Cholesterol Test
• Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
• Trophos reaches mid-point of Phase II Clinical Trial of TRO19622 in painful diabetic neuropathy
• DIAMYD ANNOUNCES COMPLETION OF TYPE 1 DIABETES VACCINE TRIAL
• Vyteris Announces First Successful Non-Invasive Delivery of Peptide Using Smart Patch Technology
• Tercica Initiates Phase II Clinical Trial with Next-Generation Growth Hormone Product for the Treatment of Short Stature
• Indevus Reports Additional Positive Phase III Trial Data for NEBIDO
• Ambrilia reports positive Phase III preliminary results showing the safety and efficacy of its prolonged-release formulation of Octreotide
• Generex Biotechnology Receives Regulatory Approval to Initiate Phase III Clinical Trial for Generex Oral-lyn in First of the Global Locations Selected by the Company
• Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX)
• Oramed Pharmaceuticals Commences Phase 1B Clinical Trials
• Merck and Schering-Plough Respond To Issues Raised About ENHANCE Clinical Trial
• Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
• Velcura can begin clinical trials following successful IND application
• Medtronic Announces FDA Approval of CGMS iPro Continuous Glucose Recorder
• Surface Logix Achieves Objectives with SLx-4090 in Phase 2a Clinical Trial
• Phase 1 Studies Show Promise of QuatRx’s Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
• Radius Announces Launch of RAD1901 Clinical Program
• Statement from the American Diabetes Association Related to ACCORD Trial Announcement
• VGX Pharmaceuticals announces the IND filing of VGX-3200, a novel DNA therapy that utilizes GHRH for the treatment of cancer cachexia and anemia
• Unigene Initiates Phase I/II Clinical Study for Oral Calcitonin
• Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
• DIAMYD UPDATES FDA IND APPROVAL STATUS FOR PHASE III DIAMYD DIABETES STUDY IN THE US
• Depomed Reports Positive Efficacy Data From a Phase 2 Trial of Gabapentin GR(TM) in the Treatment of Menopausal Hot Flashes
• Generex Biotechnology receives another regulatory approval to conduct Phase III clinical trial for Generex Oral-lyn™ for one of the largest global locations selected by the Company
• Abbott Receives FDA Approval for SIMCOR® (Niaspan® / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
• AMAG Pharmaceuticals, Inc. Announces FDA Acceptance for Filing of Ferumoxytol New Drug Application in Chronic Kidney Disease
• InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
• Duramed\'s Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
• NPIL Research & Development Limited commences Phase I trials on new molecule
• Duramed\'s Lo SEASONIQUE(R) NDA Accepted for Filing by FDA
• Oculus Innovative Sciences Announces Positive Top-Line Phase II Data with Microcyn® Technology in Mildly Infected Diabetic Foot Ulcers
• EnteroMedics Announces Planned Expansion of EMPOWER Pivotal Study for Obesity to 300 Patients
• Metabasis Therapeutics Completes Enrollment of Its Proof-of-Concept Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
• Athersys Announces Summary Results for Phase 1 Safety Study of Its Novel Obesity Drug
• Akesis Pharmaceuticals Doses First Patient in Phase IIa Trial
• PPD confirms Takeda\'s NDA filing of alogliptin with U.S. Food and Drug Administration
• VIVUS Completes Enrollment in EQUATE (OB-301) Trial
• Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
• Unigene Successfully Completes Phase I/II Clinical Study for Oral Calcitonin
• More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
• FDA Approves Abbott\'s FreeStyle Navigator® Continuous Glucose Monitoring System
• Oculus Innovative Sciences Announces Additional Phase II Data for Microcyn Technology in Mildly Infected Diabetic Foot Ulcers
• DIAMYD GETS AUTHORIZATION TO BEGIN PHASE III STUDY IN THE US
• Glycotex completes enrolment in phase IIA study of lead candidate GLYC-101 for wound healing
• Oramed Pharmaceuticals Successfully Completes Phase 1B Clinical Trials of Oral Insulin Capsule
• Hollis-Eden Pharmaceuticals Reports Positive Preliminary Data from Ongoing Phase I/II Clinical Trial with TRIOLEX(TM) in Obese Insulin Resistant Subjects
• Akesis Pharmaceuticals Provides Preliminary Data from Phase IIa Trial of AKP-020 for Type 2 Diabetes
• Phosphagenics today announced that it has received ethics approval to commence treating patients with Type 1 diabetes in a Phase 2 clinical trial using its patented transdermal insulin delivery system, TPM/Insulin
• Elixir Pharmaceuticals, Inc., announced today new data on the role of ghrelin antagonism in the regulation of metabolism and as a potential treatment for Type 2 diabetes.
• Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
• VIVUS Completes Enrollment in Phase 3 EQUIP (OB-302) Trial
• New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
• TAXUS® Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
• Phase III studies of investigational Trilipix™ (SLV348/ABT-335), in combination with statins, meets primary endpoints on improving LDL, triglycerides and HDL
• Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
• Pfizer Statement on Exubera Labeling Update in the United States
• KYTHERA BIOPHARMACEUTICALS ANNOUNCES SECOND PHASE II CLINICAL TRIAL WITH ADIPOLYTIC AGENT FOR REDUCTION OF SUBMENTAL FAT
• AtheroGenics Announces Encouraging Interim Results From Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
• Sirtris Announces SRT501 Lowers Glucose in Twice-Daily Dosing Clinical Trial; Study Suggests Dose Response for Proprietary Formulation of Resveratrol in Type 2 Diabetics
• Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx® GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
• Aldagen Announces Initiation of ALD-101 Phase III Trial for Improving Cord Blood Transplants in Pediatric Patients with Inherited Metabolic Diseases
• VIVUS Completes Enrollment in the Third Phase 3 CONQUER (OB-303) Trial
• Orexigen Therapeutics Announces Completion of Enrollment in Second of Four Phase III Clinical Trials for Contrave
• FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
• Two Merck Medicines Recommended for Approval in the European Union
• NOVAGALI PHARMA Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT for Diabetic Macular Edema
• Metabasis Therapeutics Announces Positive Results in the Phase 2a Clinical Trial for MB07803, Its Product Candidate for the Treatment of Type 2 Diabetes
• FDA Grants Market Clearance for the LipiScan™ Coronary Imaging System Developed By InfraReDx, Inc.
• DiaMedica Completes Enrollment in Phase II Clinical Trial for DM-83
• Osteologix IND for NB S101 for Osteoporosis Accepted by FDA
• LifeCycle Pharma Announces Positive Data from LCP-AtorFen Phase II Clinical Program
• Piramal Life Sciences Initiates Phase I Trials with a New Molecule for Type II Diabetes in Europe